Showing 5231-5240 of 9475 results for "".
- Survey: Parents Extremely Worried About the Physical and Emotional Toll that Severe Acne Takes on Teenshttps://practicaldermatology.com/news/survey-parents-extremely-worried-about-the-physical-and-emotional-toll-that-severe-acne-takes-on-teens/2460734/Parents are very worried about the effects of severe acne on their teens, according to a new survey sponsored by Sun Pharma, in collaboration with the American Acne and Rosacea Society (AARS). The survey, which polled 250 parents of teenagers with severe nodular or cystic acne, sho
- About Three-Quarters of Americans Wish They Had Taken Better Care of Themselves During the Pandemichttps://practicaldermatology.com/news/about-three-quarters-of-americans-wish-they-had-taken-better-care-of-themselves-during-the-pandemic/2460732/Seventy-four percent of people say they wish they’d taken better care of themselves this past year, including many admitting to sub-par skincare and grooming, finds a new survey of more than 2,022 people by
- Journey Medical to Acquire Dermira's Qbrexzahttps://practicaldermatology.com/news/journey-medical-to-acquire-dermiras-qbrexza/2460731/Journey Medical Corporation, a partner company of Fortress Biotech, Inc., has entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. The transaction is expected to close early in the secon
- SkinKick Launches Acne System at Ulta Beautyhttps://practicaldermatology.com/news/skinkick-launches-acne-system-at-ulta-beauty/2460725/SkinKick’s Acne KickPRO™ Duo is the brand’s first Ulta Beauty™ exclusive. The two-step homeopathic treatment for acute acne, began rolling out in February at Ulta Beauty online and in-stores nationwide. SkinKick is a pa
- Aditxt to Initiate First In-Human Clinical Trials with its Therapeutics Programs in Psoriasishttps://practicaldermatology.com/news/aditxt-to-initiate-first-in-human-clinical-trials-with-its-therapeutics-programs-in-psoriasis/2460724/Aditx Therapeutics, Inc.’s AditxtReprogramming Therapeutics Division is preparing its to begin first-in-human clinical
- Cetaphil Launches Sensitive Skin Awareness Weekhttps://practicaldermatology.com/news/cetaphil-launches-sensitive-skin-awareness-week/2460720/Happy Sensitive Skin Awareness Week! Sponsored by Cetaphil, the weeklong program kicks off on March 22nd and runs through March 28th. It will feature a lineup of dermatologists, influencers, and experts who wil
- AccuTec Blades: New Catalog Launches AccuThrive Brandhttps://practicaldermatology.com/news/accutec-blades-new-catalog-launches-accuthrive-brand/2460719/Introducing the newAccuThrive® medical brand, AccuTec Blades® Inc. has published its 2021 histology catalog. The 2021 AccuThrive blades portfolio highlights
- Snacking on Almonds May Smooth Wrinkles, Reduce Dark Spotshttps://practicaldermatology.com/news/snacking-on-almonds-may-smooth-wrinkles-reduce-dark-spots/2460717/Snacking on almonds may help reduce wrinkles and skin pigmentation in postmenopausal women, according to a new study funded by the Almond Board of California. In this 6-month randomized controlled trial, 49 healthy postmenopausal women with Fitzpatrick skin type 1 or 2 were randomly ass
- Differin Celebrates Retinoid Awareness Week with Educational Initiativeshttps://practicaldermatology.com/news/differin-celebrates-retinoid-awareness-week-with-educational-initiatives/2460710/Following the FDA approval of Differin Gel to be sold over the-counter in 2016, Galderma embarked on a journey to educate consumers about retinoids like adapalene. In 2017, Differin launched its first ever Retinoid Education Week to continue to drive awareness. Now in its fourth year, D
- Baricitinib Performs Well in Phase 3 AA Trialhttps://practicaldermatology.com/news/baricitinib-performs-well-in-phase-3-aa-trial/2460709/Eli Lilly and Company and Incyte’s Baricitinib is the first JAK inhibitor to demonstrate hair regrowth in a Phase 3 alopecia areata (AA) trial. Patients with severe alopecia areata who took baricitinib 2-mg or 4-mg once daily showed a statistically significant improvemen